Form 4: Relay Therapeutics Officer Sells Shares

Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, reported sales of common stock totaling 40,529 shares for tax obligations and other purposes.

Summary

• Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, Inc. (RLAY), reported sales of common stock.
• On October 28, 2025, 19,135 shares were sold at $7.29 per share to cover income tax withholding obligations upon the vesting of 47,897 restricted stock units (RSUs) on October 27, 2025. This was a non-discretionary sale.
• On October 29, 2025, an additional 21,394 shares were sold at a weighted average price of $7.50 per share, with trades ranging from $7.49 to $7.52.
• Following these transactions, Peter Rahmer beneficially owns 337,469 shares, which includes 108,919 shares underlying RSUs.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales, primarily for tax obligations related to RSU vesting, which is a neutral event. There is no indication of positive or negative sentiment beyond the standard reporting of transactions.

Positives

• The sale on October 28, 2025, was explicitly stated as non-discretionary and for tax withholding obligations, indicating a routine event rather than a discretionary sale based on negative sentiment.

Negatives

• Insider sales, even for tax purposes, reduce the officer's direct equity stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which primarily reports past insider transactions.

Management Comments

• The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
• The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide broader industry context or trends.

Comparison to Industry Standards

• Not applicable, as this filing reports specific insider transactions rather than operational or financial results that can be benchmarked against industry standards or competitors.

Corporate Governance

Stakeholder Impact

• Shareholders: The sales represent a slight reduction in the officer's direct ownership, but the tax-related portion is a routine event. The overall impact on shareholder confidence is likely minimal given the nature of the transactions.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares sold at each respective price within the reported range upon request by the SEC, the Issuer, or a security holder.

Key Dates

Recommendation

This Form 4 filing details routine insider stock sales, primarily for tax obligations related to RSU vesting. Such transactions are common and generally do not signal a significant change in company fundamentals or management's long-term outlook. Therefore, it does not provide a basis for a change in investment recommendation; a 'hold' stance is appropriate as the filing itself does not present new information warranting a 'buy' or 'sell' decision.

Keywords

Relay Therapeutics, RLAY, Insider Trading, Form 4, Stock Sale, Officer Transaction, Peter Rahmer, Restricted Stock Units, RSUs, Tax Withholding